Meeting
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
Authors
Wim van Boxtel
Radboud University Medical Center, Nijmegen, Netherlands
Wim van Boxtel , Maike Uijen , Chantal Driessen , Sjoert Pegge , Stefan M. Willems , Marianne Jonker , Tim Dijkema , Ilse van Engen - van Grunsven , Carla M.L.- Van Herpen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03729297
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6529)
DOI
10.1200/JCO.2020.38.15_suppl.6529
Abstract #
6529
Poster Bd #
190
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen
Poster
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
First Author: Maliheh Mohamadpour
Poster
2018 ASCO Annual Meeting
Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).
First Author: Laura Locati
Poster
2016 ASCO Annual Meeting
Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
First Author: Youjin Kim